GSK PLC (GLAXF)
22.65
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
GSK Net Income (Quarterly): 1.327B for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.327B |
December 31, 2023 | 434.69M |
September 30, 2023 | 1.854B |
June 30, 2023 | 2.033B |
March 31, 2023 | 1.811B |
December 31, 2022 | 1.758B |
September 30, 2022 | 12.74B |
June 30, 2022 | 1.053B |
March 31, 2022 | 2.418B |
December 31, 2021 | 295.22M |
September 30, 2021 | 1.886B |
June 30, 2021 | 1.950B |
March 31, 2021 | 1.479B |
December 31, 2020 | 893.26M |
September 30, 2020 | 1.608B |
June 30, 2020 | 2.806B |
March 31, 2020 | 2.006B |
December 31, 2019 | 1.673B |
September 30, 2019 | 1.912B |
June 30, 2019 | 1.239B |
March 31, 2019 | 1.081B |
December 31, 2018 | 1.563B |
September 30, 2018 | 1.847B |
June 30, 2018 | 600.96M |
March 31, 2018 | 763.39M |
Date | Value |
---|---|
December 31, 2017 | -725.04M |
September 30, 2017 | 1.587B |
June 30, 2017 | -230.10M |
March 31, 2017 | 1.296B |
December 31, 2016 | 319.24M |
September 30, 2016 | 1.061B |
June 30, 2016 | -624.85M |
March 31, 2016 | 403.69M |
December 31, 2015 | -536.96M |
September 30, 2015 | 833.66M |
June 30, 2015 | 228.23M |
March 31, 2015 | 12.26B |
December 31, 2014 | 1.634B |
September 30, 2014 | 669.49M |
June 30, 2014 | 1.101B |
March 31, 2014 | 1.105B |
December 31, 2013 | 3.984B |
September 30, 2013 | 1.503B |
June 30, 2013 | 1.605B |
March 31, 2013 | 1.493B |
December 31, 2012 | 1.361B |
September 30, 2012 | 1.745B |
June 30, 2012 | 1.960B |
March 31, 2012 | 2.055B |
December 31, 2011 | 1.967B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
295.22M
Minimum
Dec 2021
12.74B
Maximum
Sep 2022
2.159B
Average
1.785B
Median
Net Income (Quarterly) Benchmarks
Adaptimmune Therapeutics PLC | -48.50M |
Biodexa Pharmaceuticals Plc | -- |
Verona Pharma PLC | -25.79M |
NuCana PLC | -8.673M |
Autolus Therapeutics PLC | -52.69M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 9.339B |
Total Expenses (Quarterly) | 7.449B |
EPS Diluted (Quarterly) | 0.3222 |
Enterprise Value | 108.86B |
Gross Profit Margin (Quarterly) | 73.24% |
Profit Margin (Quarterly) | 14.21% |
Earnings Yield | 5.63% |
Operating Earnings Yield | 8.59% |
Normalized Earnings Yield | 6.218 |